EVLO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 geg. 2024 @ 17:35):

Stats
Šios dienos apimtis	6 403.00
Vidutinė apimtis	23 426.00
Rinkos kapitalizacija	11 390.00
EPS	$0 ( 2024-05-13 )
Kita pelno data	( $0 ) 2024-06-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-07	Bodmer Mark	Buy	6 625	Common Stock
2023-11-08	Bodmer Mark	Sell	3 163	Common Stock
2023-11-07	Bodmer Mark	Sell	6 625	Restricted Stock Units
2023-11-07	Mchale Duncan	Buy	6 500	Common Stock
2023-11-08	Mchale Duncan	Sell	3 103	Common Stock

INSIDER POWER
86.52
Last 96 transactions
Buy: 11 679 076 \| Sell: 749 652

Evelo Biosciences Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Evelo Biosciences Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-26.28

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-26.28

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-3.09

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.37

Financial Reports:

No articles found.

Evelo Biosciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Evelo Biosciences Inc

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Realaus laiko atnaujinimai Evelo Biosciences Inc [EVLO]

Upcoming Earnings Alert

Evelo Biosciences Inc Options Data

Calls

Puts